Get started
Author

Sebastian Weis

Measuring signatures of host resistance, disease tolerance, and damage in human sepsis: a prospective cohort study
2026 · Arnab Chowdhury, Rachel E. Powell, et al. · Intensive Care Medicine · 5
PDF
Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)
2026 · Madiha Hashmi, Rashan Haniffa, et al. · Critical Care Medicine · 1
Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1) - a randomized, placebo-controlled phase IIa dose escalation trial targeting disease tolerance to infection
2026 · Sebastian Weis, Luís Ferreira Moita, et al. · medRxiv
PDF
Impact of generic market entry on the consumption of last-resort antibiotics in six European countries
2026 · Caroline Schweizer, Sebastian Weis, et al. · Clinical Microbiology and Infection
Guardian of two galaxies: Senescence-associated immune cells control disease tolerance and aging
2026 · Wolfgang Vivas, Sebastian Weis · Immunity
Community-acquired pneumonia: Disease course prediction with a 5-gene signature
2026 · Kirsten, Holger, Weis, Sebastian, et al. · Fraunhofer-Publica (Fraunhofer-Gesellschaft)
Community-Acquired Pneumonia
2026 · Holger Kirsten, Sebastian Weis, et al. · CHEST Pulmonary
MassIVE MSV000101056 - Sepsis hibernation in disease tolerance - liver
2026 · Weis, Sebastian · UC San Diego
MassIVE MSV000101068 - Sepsis hibernation in disease tolerance - BAT and muscles
2026 · Weis, Sebastian · UC San Diego
MassIVE MSV000101067 - Sepsis hibernation in disease tolerance - Plasma
2026 · Weis, Sebastian · UC San Diego
Works count: 10
Citation count: 6
H-index: 1
I10-index:
Year
Topic
Type